Novartis will license in a new drug it has been developing with Molecular Partners to treat Covid-19, the Swiss company said on January 10, after getting positive trial data.

Novartis AG said on January 4 a U.S. court of appeals upheld the validity of a dosage regimen patent for the company’s multiple sclerosis treatment Gilenya, allowing a permanent injunction against Chinese generic drugmaker HEC Pharma to stay in place until the patent expires in 2027.

The U.S. Food and Drug Administration approved Novartis’ Leqvio (inclisiran), the first small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.

Novartis is expanding the company’s position in gene therapy and retinal diseases with the $1.5 billion acquisition of UK-based ocular gene therapy company Gyroscope Therapeutics. 

Novartis and BeiGene bookended 2021 with collaborative deals. In January, Novartis licensed the China-based company’s checkpoint inhibitor, tislelizumab. On December 20, the Swiss pharma giant announced the licensing of the late-stage TIGIT inhibitor ociperlimab to bolster Novartis’ immunotherapy pipeline.

J.P. Morgan Chase put an end to the uncertainty surrounding its annual health care conference, announcing that the 40th edition will move to a virtual format.

Novartis dropped out of the company’s deal to fund Mesoblast’s floundering COVID-19 treatment.

Novartis is going full steam ahead with the company’s cancer development efforts, posting positive results from two ongoing trials for lymphoma and leukemia.

Novartis hopes to still play a role in the development of Covid-19 treatments with ongoing research for a pill that could work broadly against coronaviruses, not just the one that causes Covid-19, chief executive Vas Narasimhan told Reuters.

Swiss drug giant Novartis and Belgian pharma company UCB announced a deal to co-develop and commercialize two products targeting Parkinson’s disease, UCB0599 and UCB7853.